儿童MHC II类缺陷移植生存与长期疾病结局改善
该研究回顾性分析了1995至2018年在Great North Children's Hospital接受首次造血干细胞移植的25例MHC II类缺陷患儿,中位随访2.9年。
要点
- 2008年后移植策略使MHC II类缺陷患儿总生存率从33%提升至94%。
- 2008年后移植者中,MFD和UD供者总生存率均为100%,HID为85%。
- 所有存活者均无显著感染或自身免疫,且脱离免疫球蛋白替代。
核心结论
- 改变移植策略显著改善了MHC II类缺陷患儿的移植结局。
研究设计与样本
- 回顾性分析1995至2018年在Great North Children's Hospital接受首次HCT的25例MHC II类缺陷患儿。
主要发现
- 无患者发生III-IV级急性或慢性GVHD。
- 所有存活者均脱离免疫球蛋白替代,对破伤风和流感嗜血杆菌有保护性疫苗反应,无显著感染或自身免疫。
关键数值与推荐
- 诊断时中位年龄6.5个月(出生至7.5岁),移植时中位年龄21.4个月(0.1-7.8岁)。
- 供者类型:MFD 6例,UD 12例,HID 7例;68%使用外周血干细胞。
- 84%患者采用基于treosulfan的预处理;84%接受alemtuzumab(n=14)或抗胸腺细胞球蛋白(n=8)作为血清治疗。
- 最新供者髓系和淋巴细胞嵌合率中位数分别为100%(范围0-100)和100%(范围64-100)。
临床怎么用
- 对于MHC II类缺陷患儿,采用基于treosulfan的预处理及alemtuzumab或ATG血清治疗的移植策略可显著改善生存。
- 移植后存活者可脱离免疫球蛋白替代,但CD4+ T淋巴细胞数可能持续偏低,需监测免疫重建。
局限性
- 回顾性单中心研究,样本量较小(25例),2008年前亚组仅6例。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
MHC class II deficiency is a rare, but life-threatening, primary combined immunodeficiency. Hematopoietic cell transplantation (HCT) remains the only curative treatment for this condition, but transplant survival in the previously published result was poor. We analyzed the outcome of 25 patients with MHC class II deficiency undergoing first HCT at Great North Children's Hospital between 1995 and 2018. Median age at diagnosis was 6.5 months (birth to 7.5 years). Median age at transplant was 21.4 months (0.1-7.8 years). Donors were matched family donors (MFDs; n = 6), unrelated donors (UDs; n = 12), and haploidentical donors (HIDs; n = 7). Peripheral blood stem cells were the stem cell source in 68% of patients. Conditioning was treosulfanbased in 84% of patients; 84% received alemtuzumab (n = 14) or anti-thymocyte globulin (n = 8) as serotherapy. With a 2.9-year median follow-up, OS improved from 33% (46-68%) for HCT before 2008 (n = 6) to 94% (66-99%) for HCT after 2008 (n = 19; P = .003). For HCT after 2008, OS according to donor was 100% for MFDs and UDs and 85% for HIDs (P = .40). None had grade III-IV acute or chronic graft-versus-host disease. Latest median donor myeloid and lymphocyte chimerism were 100% (range, 0-100) and 100% (range, 64-100), respectively. Latest CD4+ T-lymphocyte number was significantly lower in transplant survivors (n = 14) compared with posttransplant disease controls (P = .01). All survivors were off immunoglobulin replacement and had protective vaccine responses to tetanus and Haemophilus influenzae. None had any significant infection or autoimmunity. Changing transplant strategy in Great North Children's Hospital has significantly improved outcomes for MHC class II deficiency.
引用
- Lum SH, Anderson C, McNaughton P, et al. Improved transplant survival and long-term disease outcome in children with MHC class II deficiency. Blood. 2020. PMID: 31932845. doi:10.1182/blood.2019002690
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。